Perioperative Use of Desmopressin (DDAVP) in Breast Cancer

Breast Cancer Clinical Trial

Official title:

Perioperative Administration of Desmopressin to Subjects With Breast Cancer: A Phase IIa, Dose-Escalation Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01606072
• Other study ID #: DDAVP
• Status: Completed
• Phase: Phase 2
• First received: May 11, 2012
• Last updated: August 27, 2015
• Start date: November 2011
• Est. completion date: July 2015

Study information

• Verified date: August 2015
• Source: Laboratorio Elea S.A.C.I.F. y A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
• Study type: Interventional

Clinical Trial Summary

The propose for this study is to evaluate the safety and tolerability of desmopressin when administered perioperatively to patients with breast cancer undergoing surgery as first treatment, and select the optimum dose for the clinical development of the product.

Description:

Breast cancer is one of the most commonly diagnosed malignancies among women, and its mortality is related to the capacity of tumor cells to invade and produce metastases. It is postulated that tumor manipulation during surgery results in the release of tumor cells into circulation or the lymphatic system, and that these released cells survive due to aggregation among them or with platelets through the formation of a fibrin layer on the embolus. Tumor cells surviving transportation through circulation will join blood vessels and invade vascular walls, forming metastases. The interruption of this process might reduce survival of tumor cells and thus the formation of metastases from breast cancer cells in the lungs or other tissues.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years to 60 Years

Eligibility

Inclusion Criteria:

• a. Female subjects from 21 to 60 years of age, who have voluntarily signed the informed consent form.

b. Histological/cytological diagnosis of breast carcinoma obtained at least 21 days before inclusion into the study.

c. Candidate for radical mastectomy and requiring resection of axillary lymph nodes or sentinel node.

d. In case of women of childbearing potential, an adequate birth control method (intrauterine device, barrier methods, or tubal ligation) should be used throughout the study. Post-menopausal women should have menopause confirmed by biochemical parameters.

e. Adequate organic function, defined by the following parameters:

• Electrocardiogram (ECG) with no significant anomalies, performed within 14 days prior to surgery.

• The following laboratory results, obtained 7 days before surgery:

• Hemoglobin = 11 g/dL

• Total white blood cell count = 4,000/mm3

• Total neutrophil count 1,500/mm3

• Platelet count within normal limits

• Total bilirubin =1.5 x UNL or 2.5 x UNL in case of hepatic metastasis

• Transaminases ALT/GPT and AST/GOT = 1.5 x UNL

• Creatinine clearance >50 mg/dL

• CT scan with oral and endovenous contrast* of chest, pelvis, and abdomen, and bone scan, conducted within 28 days prior to surgery. Images taken not longer than 90 days before surgery are also acceptable.

• In case contrast is contraindicated, CT with no contrast or MRI will be performed.

f. Subject with performance status (ECOG) = 0.

Exclusion Criteria:

• a. Synchronic bilateral breast cancer. b. Symptoms of metastasis or evidence of metastasis from images: chest spiral CT scan, abdomen/pelvis spiral CT scan, brain spiral CT/MRI (in case of brain metastasis signs), and bone scan.

c. The patient is pregnant or breastfeeding. d. The patient is presently using hormonal contraceptives or under hormonal treatment. She would be eligible if oral contraceptives were discontinued or if the hormonal treatment finished 30 days before surgery and the patient agreed to use another contraceptive method.

e. Patients with a history or presence of congestive heart failure, blood hypertension, angina pectoris or heart arrhythmia, thromboembolic disease, diabetes type I or II, or any underlying coronaropathy detected in pre-surgical evaluations.

f. Mentally-impaired patients. g. Patients with known hypersensitivity to DDAVP or vasopressin, o with severe von Willebrand's disease (VWD), defined by a VWF activity <10%IU/dL, or type 2B VWD, defined by an increased ristocetin-induced platelet aggregation (RIPA) at low concentrations of ristocetin or with hemophilia.

h. Patients with a history of seizures. i. Patients with renal impairment (creatinine clearance < 50 mL/min calculated by the Cockcroft-Gault formula), hyponatremia or with a history of hyponatremia.

j. Patients with syndrome of inadequate secretion of antidiuretic hormone. k. Patients with positive serology for the hepatitis B or C virus and/or HIV. l. Patients with known hepatic disease (diagnosed cirrhosis, hepatic enzymes (GOT/GPT) > 1.5 x UNL, Total bilirubin > 1.5 x UNL).

m. Patients with active infections. n. Patients with other malignant diseases, with the exception of, non-melanoma skin cancer, or cervix cancer in situ, or any other tumor that has received adequate treatment and shows a disease-free time = 5 years.

o. Patients participating in another clinical study or cases in which less than 4 weeks have elapsed since participation in another clinical study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Desmopressin
20 patients in 5 groups 4 each, advancing progressively to each dose level.

Locations

Country	Name	City	State
Argentina	Hospital Interzonal General De Agudos EvaPeron	Buenos Aires

Sponsors (1)

Lead Sponsor	Collaborator
Laboratorio Elea S.A.C.I.F. y A.

Country where clinical trial is conducted

Argentina, 

References & Publications (1)

Weinberg RS, Grecco MO, Ferro GS, Seigelshifer DJ, Perroni NV, Terrier FJ, Sánchez-Luceros A, Maronna E, Sánchez-Marull R, Frahm I, Guthmann MD, Di Leo D, Spitzer E, Ciccia GN, Garona J, Pifano M, Torbidoni AV, Gomez DE, Ripoll GV, Gomez RE, Demarco IA, A — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Selection of the higher safe dose level for ensuing clinical trials	One of the three dose levels assessed in this study will be selected for further clinical testing in adults: 0,50 mg, 1,0 mg, 1,25 mg, 1,5 mg or 2,0 mg.	Up to 2 years	Yes
Secondary	Evidence of V2 Receptor Expression		Baseline	No
Secondary	Evidence of CTC (CIRCULATING TUMOR CELLS)		Baseline	No
Secondary	Evidence of Von Willebrand factor antigen (VWF:Ag)		Baseline	No
Secondary	Evidence of CTC (circulating tumor cells)		30 minutes pre surgery and 24 hours post the surgery	No
Secondary	Evidence of CTC (circulating tumor cells)		2 Weeks	No
Secondary	Evidence of CTC (circulating tumor cells)		1 Month	No
Secondary	Evidence of CTC (circulating tumor cells)		3 Months	No
Secondary	Evidence of CTC (circulating tumor cells)		6 Months	No
Secondary	Evidence of CTC (circulating tumor cells)		12 Months	No
Secondary	Evidence of Von Willebrand factor antigen (VWF:Ag)		120 minutes post the surgery	No
Secondary	Evidence of VWF activity (ristocetin cofactor, VWF:RCo)		baseline	No
Secondary	Evidence of VWF activity (ristocetin cofactor, VWF:RCo)		120 minutes post the surgery	No
Secondary	Evidence of FVIII coagulant activity (FVIII:C)		baseline	No
Secondary	Evidence of FVIII coagulant activity (FVIII:C)		120 minutes post the surgery	No
Secondary	Evidence of euglobulin lysis time		baseline	No
Secondary	Evidence of euglobulin lysis time		120 minutes post the surgery	No